Document is current
Any future updates will be listed below
-
Authors
Martin-Sancho, Laura
Tripathi, Shashank
Rodriguez-Frandsen, Ariel
Pache, Lars https://orcid.org/0000-0002-4193-1042
Sanchez-Aparicio, Maite https://orcid.org/0000-0001-6556-5924
McGregor, Michael J.
Haas, Kelsey M. https://orcid.org/0000-0002-1463-6726
Swaney, Danielle L.
Nguyen, Thong T.
Mamede, João I. https://orcid.org/0000-0002-6048-1876
Churas, Christopher
Pratt, Dexter
Rosenthal, Sara B.
Riva, Laura
Nguyen, Courtney
Beltran-Raygoza, Nish
Soonthornvacharin, Stephen
Wang, Guojun
Jimenez-Morales, David https://orcid.org/0000-0003-4356-6461
De Jesus, Paul D.
Moulton, Hong M.
Stein, David A.
Chang, Max W. https://orcid.org/0000-0002-4526-489X
Benner, Chris https://orcid.org/0000-0002-4618-0719
Ideker, Trey https://orcid.org/0000-0002-1708-8454
Albrecht, Randy A. https://orcid.org/0000-0003-4008-503X
Hultquist, Judd F.
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Chanda, Sumit K. https://orcid.org/0000-0001-9399-7927
- License Information
-
More Information
Article History
Received: 9 May 2020
Accepted: 18 August 2021
First Online: 23 September 2021
Competing interests
: The N.J.K. Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. N.J.K. has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics and Interline Therapeutics, is a shareholder of Tenaya Therapeutics and has received stocks from Maze Therapeutics and Interline Therapeutics. The remaining authors declare no competing interests.
